# Secukinumab

## Cosentyx 150mg prefilled pen

| 藥物代碼 | ICOSE |
| :--- | :--- |
| 適應症 | Ankylosing spondylitisPlaque psoriasis \(Moderate to Severe\), In patients who are candidates for systemic therapy or phototherapyPsoriatic arthritis |
| 副作用 | \[Common\]Diarrhea \(2.6% to 4.1% \), Nasopharyngitis \(Ankylosing spondylitis, 2% or more ; plaque psoriasis, 11.4% to 12.3% ; psoriatic arthritis, 2% or more \), Upper respiratory infection \(Ankylosing spondylitis, 2% or more ; plaque psoriasis, 2.5% to 3.2% ; psoriatic arthritis, 2% or more \)\[Serious\]Crohn's disease \(Ankylosing spondylitis, 0.87% \), Crohn's disease, Exacerbation \(Plaque psoriasis, 0.09% \), Inflammatory bowel disease, Ulcerative colitis \(Ankylosing spondylitis, 0.5%; plaque psoriasis, 0.06% \), Ulcerative colitis, Exacerbation \(Plaque psoriasis, 0.06% \), Anaphylaxis, Infectious disease \(Ankylosing spondylitis, 31% ; plaque psoriasis \(up to 12 weeks\), 28.7%; plaque psoriasis \(up to 52 weeks\), 47.5% ; psoriatic arthritis, 29% \) |
| 禁忌 | Hypersensitivity to secukinumab or any component of the product. |
| 藥物保存方式 | 2-8℃ 避光 |
| 用法用量 | Adult Ankylosing spondylitis ‧May be given with or without a loading dose ‧With a loading dose, 150 mg subQ at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter ‧Without a loading dose, 150 mg subQ every 4 weeks  Plaque psoriasis \(Moderate to Severe\), In patients who are candidates for systemic therapy or phototherapy ‧Initial, 300 mg \(2 injections of 150 mg\) subQ at weeks 0, 1, 2, 3, and 4; some patients may only need 150 mg ‧Maintenance, 300 mg \(2 injections of 150 mg\) subQ every 4 weeks; some patients may only need 150 mg ‧Plaque psoriasis with comorbid psoriatic arthritis: Initial, 300 mg \(2 injections of 150 mg\) subQ at weeks 0, 1, 2, 3, and 4; some patients may only need 150 mg ‧Plaque psoriasis with comorbid psoriatic arthritis: Maintenance, 300 mg \(2 injections of 150 mg\) subQ every 4 weeks; some patients may only need 150 mg  Psoriatic arthritis ‧May be given with or without a loading dose ‧With a loading dose, 150 mg subQ at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may give with or without methotrexate; may consider dose of 300 mg if active disease persists ‧Without a loading dose, 150 mg subQ every 4 weeks; may give with or without methotrexate; may consider a dose of 300 mg if active disease persists ‧Psoriatic arthritis with comorbid plaque psoriasis: Initial, 300 mg \(2 injections of 150 mg\) subQ at weeks 0, 1, 2, 3, and 4; some patients may only need 150 mg ‧Psoriatic arthritis with comorbid plaque psoriasis: Maintenance, 300 mg \(2 injections of 150 mg\) subQ every 4 weeks; some patients may only need 150 mg |
| 肝功能異常 | 無需調整劑量  There are no dosage adjustments provided in the manufacturer's labeling |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 可能安全 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | SC |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | ■The removable cap contains natural rubber latex and should not be handled by latex-sensitive individuals. ■Allow Sensoready\(R\) pen to reach room temperature \(15 to 30 minutes\) before injecting; administer within 1 hour after removing from refrigerator. ■Administer each injection at a different anatomic location \(eg, upper arms, thighs, or any quadrant of abdomen\) than the previous injection; avoid areas where skin is tender, bruised, erythematous, indurated, or affected by psoriasis. |

